Leerink Swann reiterated their outperform rating on shares of Eli Lilly and Co. (NYSE:LLY) in a research report released on Saturday morning. Leerink Swann currently has a $92.00 price objective on the stock, down from their previous price objective of $102.00.
Several other research firms have also commented on LLY. Argus boosted their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a research report on Tuesday, August 2nd. Morgan Stanley set a $73.00 target price on shares of Eli Lilly and and gave the company a hold rating in a report on Thursday. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $92.00 target price on the stock in a report on Friday, August 5th. BMO Capital Markets restated an outperform rating and issued a $94.00 target price on shares of Eli Lilly and in a report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a neutral rating to a buy rating and upped their target price for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $108.34.
Eli Lilly and (NYSE:LLY) traded up 1.65% on Friday, hitting $69.12. 8,620,682 shares of the stock traded hands. The stock has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $88.16. The firm’s 50-day moving average price is $76.69 and its 200-day moving average price is $77.92.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $0.96 by $0.08. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the prior year, the firm earned $0.89 earnings per share. Eli Lilly and’s quarterly revenue was up 4.7% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and will post $3.55 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s dividend payout ratio (DPR) is currently 88.70%.
In other news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock valued at $4,979,889,000 after buying an additional 1,350,329 shares during the period. Franklin Resources Inc. boosted its position in shares of Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock valued at $2,238,939,000 after buying an additional 685,898 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in shares of Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock valued at $2,100,581,000 after buying an additional 289,681 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock valued at $1,825,790,000 after buying an additional 668,184 shares during the period. Finally, BlackRock Fund Advisors boosted its position in shares of Eli Lilly and by 2.5% in the third quarter. BlackRock Fund Advisors now owns 17,629,570 shares of the company’s stock valued at $1,414,949,000 after buying an additional 423,179 shares during the period. Institutional investors own 75.11% of the company’s stock.
Eli Lilly and Company Profile